Research Roundup

Debbie Rigby rounds up the latest in research news

Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level

In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at least 12 years of age and who had mild, persistent asthma to receive mometasone (an inhaled glucocorticoid), tiotropium (a long-acting muscarinic antagonist), or placebo. The patients were categorized according to the sputum eosinophil level (<2% or ≥2%). The majority of patients with mild, persistent asthma had a low sputum eosinophil level and had no significant difference in their response to either mometasone or tiotropium as compared with placebo.

New Engl J Med, first published May 19, 2019.


Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients

Subgroup analysis of the ARISTOPHANES study of older people (aged >80 years) confirms the effectivness of DOACs in reducing the rates of stroke/systemic embolism in this population. Apixaban was associated with a lower risk of major bleeding compared with warfarin, dabigatran has similar risk, and rivaroxaban was associated with a higher risk.

J Am Geriatr Soc 2019.


Pharmacist-led medication non-adherence intervention

Analysis of dispensing data of over 20,000 Australian patients demonstrates the impact of pharmacist-led medication adherence interventions on rosuvastatin, irbesartan and desvenlafaxine. Patients were enrolled in the MedScreen Compliance program. The total national cost of medication non-adherence across three prevalent conditions, hypertension, dyslipidemia and depression was $10.4 billion equating to $517 per adult.

Patient Preference and Adherence 2019;13:853–862.


Probiotic Use for the Prevention of Antibiotic- Associated Clostridium difficile Infection

C difficile has been shown to be the causative agent in 10% to 20% of antibiotic-associated diarrhea episodes. Probiotics may be recommended for CDI prevention in patients taking antibiotics, especially patients at high risk for developing CDI. Probiotics should be initiated within 2 days after the start of antibiotics and should be continued for the duration of antibiotic therapy and for up to 7 days after that therapy is completed.

Fed Pract. 2019 June;36(6):257-261.

Previous Change at the top
Next Failure to maintain professional boundaries

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply